Bioanalytical Systems names new COO of scientific services
Dr Chilton will have responsibility for the scientific services provided to the company’s customers from three locations in the US and one in the UK. For the past
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
This alliance combines Patheon’s experience and expertise in formulation development with Solvias’s reputation of excellence in pre-formulation and solid state chemistry. The partnering of Patheon and Solvias will